← Browse by Condition
Medical Condition

sbrt

Total Trials
1
Recruiting Now
1
Trial Phases
Phase 2
NCT06676722 Phase 2
Recruiting

SBRT Combined With Nimotuzumab and Tislelizumab for Oligoprogressive Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of Immunotherapy

Enrollment
20 pts
Location
China
Sponsor
The First Affiliated Hospital ...
View Trial →